Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nadofaragene firadenovec - FKD Therapies

Drug Profile

Nadofaragene firadenovec - FKD Therapies

Alternative Names: Adenovirus-Delivered Interferon Alpha-2b; Instiladrin; Nadofaragene firadenovec/Syn3; rAd-IFN; rAd-IFN/Syn3; SCH-721015; TR002

Latest Information Update: 26 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough; University of Pennsylvania
  • Developer FKD Therapies; Trizell; University of Pennsylvania
  • Class Antineoplastics; IFNA2B gene therapies
  • Mechanism of Action Gene transference; IFNA2B expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Bladder cancer; Mesothelioma

Most Recent Events

  • 20 Mar 2019 Phase-III clinical trials in Mesothelioma (Combination therapy, Second-line therapy or greater) in Russia, Australia, Europe, USA (Intrapleural) (NCT03710876)
  • 20 Mar 2019 Efficacy data from a phase II trial in Mesothelioma released by Trizell
  • 18 Oct 2018 University of Pennsylvania and Trizell plan the phase III INFINITE trial for malignant pleural Mesothelioma (Combination therapy, Second-line therapy or greater) in USA (Intrapleural) (NCT03710876)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top